Nationwide, an estimated 1.2 million people are eligible to receive medication that can prevent the spread of life-threatening HIV infection. But only roughly a third of those eligible are currently ...
The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to placebo, with dose-proportional pharmacokinetics, among adults with a low ...
Australia's taken another step in HIV prevention, with the TGA approving long-acting drug lenacapavir—but access is vital, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback